A χ2 test was used to compare the incidence of adverse effects of
the two groups. All statistical tests were two-sided, with P-value less than 0.05 considered significant. A total of 75 patients with IgA nephropathy were initially screened from five centres. After screening, 69 of these patients were deemed eligible and 68 patients ultimately completed the study. Among these 68 patients, 42 were from one centre and 26 were from the other four centres. The 68 patients (27 males, CDK inhibitor 41 females) were randomly divided into two groups: the treatment group (probucol combined with valsartan, n = 33) and the control group (valsartan only, n = 35). Table 1 shows the baseline characteristics of the treatment and control groups. The median age was 34 (range 19–67) years in the treatment group and 34 (range 18–74) years in the control group. There were no significant differences between these two groups in blood pressure, Scr, 24-h urinary protein excretion, or any of the other parameters listed in Table 1. Table 2 shows the baseline Oxford classification scores of
IgA nephropathy (M/E/S/T) in the treatment and control groups. Again, there was no significant difference Selleckchem DAPT between the two groups (P > 0.05). All 68 patients were followed for 3 years and none developed ESRD. However, 43 patients (23 (69.7%) in the treatment group, 20 (57.1%) in the control Histamine H2 receptor group) had reductions of 24-h urinary protein by 50% or more relative to baseline levels (secondary endpoint). Kaplan–Meier analysis indicated that the time to 50% reduction in 24-h urinary protein was significantly shorter in the treatment group than in the control
group, the median of two groups was 8.13 months, 19.63 months, respectively (P = 0.019) (Fig. 2). At the 1-year follow-up, the level of 24-h urinary protein in the treatment group (995.49 ± 561.13 mg) and control group (1055.84 ± 761.09 mg) were reduced by 28.4% (P = 0.02) and 28.0% (P = 0.03) compared with baseline levels (Fig. 3). At the 2-year follow-up, the mean 24-h urinary protein in the treatment group (756.65 ± 475.21 mg) was markedly reduced compared with baseline (P < 0.01); but there was no significant difference compared to the control group (1432.33 ± 1135.33 mg, P = 0.056). The mean 24-h urinary protein in the control group (1432.33 ± 1135.33 mg) was higher than the level at the 1-year follow-up (1055.84 ± 761.09 mg), but not significantly different from the baseline level (P = 0.92) (Fig. 3). At the 3-year follow-up, the 24-h urinary protein in the treatment group (1385.32 ± 999.77 mg) and the control group (1343.31 ± 941.34 mg) were comparable to the baseline levels (P = 0.99 and P = 0.66, respectively) (Fig. 3). At the 1-year and 2-year follow-ups, the mean Scr in the treatment and control groups were comparable to the baseline levels (Table 3).